Free PSA vs Total PSA Report Explained
Total PSA measures both protein-bound and unbound PSA in the blood. Free PSA is the unbound portion. The percentage free PSA (%free PSA = free PSA ÷ total PSA × 100) can help refine cancer risk in selected men, particularly when total PSA is in an intermediate or “grey-zone” range and the prostate examination is not clearly malignant. In general, a lower percentage free PSA is associated with a higher probability of prostate cancer, but it is not a diagnosis and should not be used without age, prostate volume, MRI, PSA density and other risk factors.
Why free PSA is measured
Benign prostate tissue tends to release a larger proportion of PSA in free form, while prostate cancer is often associated with a lower free fraction. Measuring both can therefore add information when total PSA alone leaves uncertainty. It is less useful when total PSA is very low or when the clinical situation already clearly requires another step.
How the percentage is calculated
If total PSA is 6 ng/mL and free PSA is 1.2 ng/mL, the percent free PSA is 20%. Laboratories may calculate it automatically. The ratio should be interpreted only when total and free PSA were measured from the same blood sample using a compatible assay.
What do common percentages mean?
Historical studies often use approximate categories such as below 10%, 10-25% and above 25%, with lower percentages associated with progressively greater cancer probability in men with intermediate total PSA. These are not universal biopsy cutoffs. Modern pathways increasingly combine MRI, PSA density and calibrated risk calculators, so a free-PSA percentage should be considered one piece of the assessment rather than a stand-alone rule.
Factors that can distort interpretation
- Prostatitis or urinary infection.
- Recent urinary retention or prostate procedures.
- Very large benign prostate.
- 5-alpha-reductase inhibitor use.
- Different laboratories or assays across serial measurements.
Free PSA versus PSA density
PSA density uses prostate volume to ask whether the PSA is proportionate to the amount of prostate tissue. Free PSA uses the biochemical form of PSA. They answer different questions and can be complementary, but prostate MRI with PSA density is now central to many modern diagnostic pathways.
What happens after an unfavourable free-PSA ratio?
It does not automatically mean biopsy. The urologist may repeat PSA, examine the prostate, calculate PSA density and obtain multiparametric MRI. Biopsy decisions are based on the total cancer risk, including MRI category, family history, age and patient preferences.
When the result needs earlier review
- Abnormal digital rectal examination.
- Persistent PSA rise on repeat testing.
- PI-RADS 4 or 5 lesion on MRI.
- Strong hereditary risk such as BRCA2 or multiple close relatives with early prostate cancer.
Free PSA should not delay evaluation when other findings are strongly suspicious
If digital rectal examination is clearly abnormal, MRI shows a high-suspicion lesion or PSA is rising markedly, repeating free PSA again and again may add little. Biomarkers are most useful when they reduce genuine uncertainty. They should not become a reason to postpone a clinically indicated MRI or biopsy pathway, nor should a favourable ratio be used to dismiss a concerning MRI finding.
When free PSA adds the most value
The test is most useful when total PSA is neither clearly low risk nor so high/suspicious that the next step is already obvious. In that intermediate zone, %free PSA may shift the estimated probability enough to support MRI, biopsy or continued monitoring.
Do not compare a free-PSA ratio obtained during prostatitis or urinary retention with a stable baseline as if they were equivalent. If the result conflicts strongly with MRI and PSA density, the clinician usually gives more weight to the complete risk assessment than to one biomarker ratio.
Where free PSA helps—and where it does not
Free-to-total PSA is most useful in the diagnostic grey zone, when total PSA is modestly elevated and the clinician is deciding whether further risk assessment is needed. Lower percentages are associated with greater cancer probability, but the result is assay- and population-dependent and should not be converted into an individual cancer percentage from a single internet table.
Once MRI, PSA density, digital rectal examination, family history and previous biopsy information are available, free PSA becomes one input among several. A reassuring ratio should not override a clearly suspicious MRI or examination.
What to bring for consultation
- Total PSA and free PSA values from the same draw.
- Previous total PSA values with dates.
- Prostate volume from ultrasound or MRI.
- MRI report/images if already done.
- Medication and family-history details.
FAQs
Is a free PSA above 25% always safe?
No. It is generally more reassuring than a low percentage in the appropriate PSA range, but cancer cannot be excluded from that number alone.
Is a free PSA below 10% cancer?
No. It raises suspicion in the right context but still requires risk assessment and often MRI/biopsy confirmation.
Should everyone with an elevated PSA get free PSA?
No. It is most useful in selected situations where it can change the next decision.
Which is better: free PSA or MRI?
They are not direct substitutes. Modern pathways usually give MRI and PSA density a central role, with biomarkers such as free PSA used selectively.
Related reading
- PSA Report Explained
- Prostate MRI Report Explained
- PI-RADS Score on MRI Explained
- HPE / Biopsy Report Explained
- Urologist in Latur
References
- European Association of Urology. EAU Guidelines on Prostate Cancer: Diagnostic Evaluation. 2026 https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation
- Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA. 1998;279(19):1542-1547.